Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Extension of Therapeutic Indications for Cetuximab
Дата публикации: 14-08-2026 07:08:00

New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
2EMA Recommends Extension of Therapeutic Indications for Serplulimab013.8831-07-2026
3Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC012.423-07-2026
4EMA Recommends Extension of Therapeutic Indications for Epcoritamab08.0424-07-2026
5EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
6EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
7EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength09.6407-08-2026
8Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC016.811-08-2026
9Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL014.7606-08-2026
10Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence01021-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.3. Источник: www.esmo.org.